Overactive Bladder clinical trials

Explore recruiting overactive bladder clinical trials.

Recruiting overactive bladder studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Overactive Bladder trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Feasibility and tolerability of 28 days intravaginal oxybutynin via the MedRing OAB system

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

An exploratory, prospective, multicenter, randomized, double blind, placebo + sham device controlled, study to assess the safety, usability, and initial efficacy of the ViXe combination for intravesical administration of XEOMIN® in the treatment of female patients with idiopathic overactive bladder (OAB).

Portugal

Therapeutic exploratory (Phase II) EU CTIS Study details

Efficacy of solifenacin, mirabegron and combination therapy in children with overactive bladder and daytime urinary incontinence (BeDry)

Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open Label, Multicenter, Baseline-controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron Prolonged-release Microgranula-based Suspension in Children from 6 Months to Less Than 3 Years of Age with Neurogenic Detrusor Overactivity

Denmark, Belgium, Poland, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicentre, randomised, double-blind, placebo-controlled clinical trial to confirm the efficacy, safety, and clinical impact of the mucosal bacterial therapeutic vaccine MV140 in women with non-complicated recurrent urinary tract infections (rUTIs).

Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

Overactive Bladder trials by city

Overactive Bladder in Toronto Overactive Bladder in Vancouver Overactive Bladder in Montreal Overactive Bladder in Calgary Overactive Bladder in Edmonton Overactive Bladder in Ottawa Overactive Bladder in Winnipeg Overactive Bladder in Quebec City Overactive Bladder in Hamilton Overactive Bladder in Kitchener Overactive Bladder in London Overactive Bladder in Halifax Overactive Bladder in New York Overactive Bladder in Los Angeles Overactive Bladder in Chicago Overactive Bladder in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease